Browse studies

Find your next paid study

1,241 recruiting studies matching your filters

A Phase IIa Clinical Trial of First-Line Cyclical Gemcitabine, Cisplatin, and Durvalumab Alternating With Pemigatinib for Advanced Biliary Tract Cancers With FGFR2 Alterations

This phase II trial tests how well giving gemcitabine, cisplatin and durvalumab alternating with pemigatinib for the treatment of biliary tract cancer with FGF…

Locally Advanced Ampulla of Vater CarcinomaLocally Advanced Biliary Tract CarcinomaLocally Advanced Extrahepatic Cholangiocarcinoma+20 more

Estimated

~$10 – $6,250

Ohio State University Comprehensive Cancer CenterNCT07780838

Phase 3

Randomized Phase III Study of Combination Osimertinib (AZD9291) and Bevacizumab Versus Osimertinib (AZD9291) Alone as First-Line Treatment for Patients With Metastatic EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC)

This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that …

Advanced Lung Non-Squamous Non-Small Cell CarcinomaMetastatic Lung Non-Squamous Non-Small Cell CarcinomaRecurrent Lung Non-Squamous Non-Small Cell Carcinoma+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT04181060

Phase 3

Randomized Phase III Trial INcorporating Pathologic Complete ReSponse in Participants With Early StaGe Non Small Cell Lung Cancer to Optimize ImmunotHerapy in The AdjuvanT Setting (INSIGHT)

This phase III trial compares durvalumab to the usual approach (patient observation) after surgery for the treatment of patients with early-stage non-small cel…

Lung Non-Small Cell CarcinomaStage II Lung Cancer AJCC v8Stage IIIA Lung Cancer AJCC v8+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06498635

Observational

A Multicenter Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-Cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leukemia

Background: Chimeric antigen receptor T-cell (CART) therapy is a form of immunotherapy which can be used to treat people with relapsed B-ALL. For those who ac…

B-AllAcute Lymphoblastic Leukemia

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT05621291

Phase 2

A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and Toxicity

Background: High-grade neuroendocrine carcinomas (HGNEC) are cancers that develop in different parts of the body, including the digestive tract, genitals, nec…

Carcinoma, NeuroendocrineTumor, NeuroendocrineTumors, Neuroendocrine+2 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT06406465

Observational

Imaging Pain in a Virtual World: Neuroimaging Biomarkers for Assessing Brain Mechanisms Mediating Virtual Reality Pain Management in Children

This study aims to use functional near-infrared spectroscopy (fNIRS) to identify and quantify pain biomarkers during burn dressing changes and pain relief indu…

Acute PainPediatric ALLProcedural Pain+1 more

Estimated

~$10 – $6,250

Nationwide Children's HospitalNCT06303687

Phase 2

Molecular Analysis for Combination Therapy Choice (ComboMATCH)

This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients …

Advanced Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+12 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)

Phase 1

Phase I Clinical Trial of Rituximab (Rtx) and Tafasitamab in Combination With Allogeneic NK Cells for Treatment of Relapsed/Refractory (r/r) B-cell Non-Hodgkin Lymphoma

This research study is for people who have relapsed or refractory B-cell non-Hodgkin's lymphoma (NHL) that has not responded to two or more lines of therapy. T…

Non Hodgkin LymphomaB-cell Non Hodgkin LymphomaDiffuse Large B Cell Lymphoma+7 more

Estimated

~$10 – $7,500

Paolo Caimi, MDNCT07225439

Phase 1

A Phase I/II Open-label Study of DJI136, a DLL3-targeted CAR-T Therapy, in Adult Patients With ES-SCLC

This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recomme…

Extensive-stage Small Cell Lung Cancer (ES-SCLC)

Estimated

~$10 – $8,750

Novartis PharmaceuticalsNCT07564401

Phase 3

A Phase 3 Open-Label, Randomized, Controlled, Global Study of Telisotuzumab Vedotin (ABBV-399) Versus Docetaxel in Subjects With Previously Treated c-Met Overexpressing, EGFR Wildtype, Locally Advanced/Metastatic Non-Squamous Non-Small Cell Lung Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. Non-small cell lung cancer (NSCLC) is a solid tumor, a disease …

Non Small Cell Lung Cancer

A Single-Arm, Phase 2 Study of Neoadjuvant Carboplatin and Mirvetuximab Soravtansine in Subjects With FRα-Expressing Advanced-Stage Serous Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess the safety and efficacy …

Epithelial Ovarian CancerFallopian Tube CancerPrimary Peritoneal Cancer+1 more

A Phase 2 Pilot Study of Mirdametinib in Relapsed Refractory Chronic Lymphocytic Leukemia

This phase II trial tests the effect of mirdametinib in treating patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has …

Recurrent Chronic Lymphocytic LeukemiaRecurrent Small Lymphocytic LymphomaRefractory Chronic Lymphocytic Leukemia+1 more

Estimated

~$10 – $5,625

National Cancer Institute (NCI)NCT07061951